The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC) is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) were shown in the CHAARTED trial in patients with metastatic high-volume disease (HVD).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
To assess the impact of metastatic burden and to update overall survival (OS) data of the GETUG-AFU15 study.
Randomized phase 3 trial of ADT plus D versus ADT alone in 385 mNCPC patients; median follow-up of 7 yr.
Primary end point was OS. Secondary end points were biochemical progression-free survival (bPFS) and radiographic progression-free survival (rPFS). Retrospective analysis was by tumor volume.
After a median follow-up of 83. 9 mo, median OS in the overall population was 62. 1 mo (95% confidence interval [CI], 49. 5-73. 7) and 48. 6 mo (95% CI, 40. 9-60. 6) for ADT plus D and ADT arms, respectively (hazard ratio [HR]: 0. 88 [95% CI, 0. 68-1. 14]; p=0. 3). Median OS in ADT plus D and ADT arms, respectively, was for HVD patients: 39. 8 mo (95% CI, 28. 0-53. 4) versus 35. 1 mo (95% CI, 29. 9-43. 6) (HR: 0. 78 [95% CI, 0. 56-1. 09]; p=0. 14), for low-volume disease (LVD) patients; median was not reached (NR; 95% CI, 69. 5-NR) and 83. 4 mo (95% CI, 61. 8-NR) (HR: 1. 02 [95% CI, 0. 67-1. 55]; p=0. 9). For upfront metastatic patients, OS was 52. 6 mo (95% CI, 43. 3-66. 8) and 41. 5 mo (95% CI, 36. 3-54. 5), respectively (HR: 0. 93 [95% CI, 0. 69-1. 25]; p=0. 6). The bPFS (HR: 0. 73 [95% CI, 0. 56-0. 94]; p=0. 014) and rPFS (HR: 0. 75 [95% CI, 0. 58-0. 97]; p=0. 030) were significantly longer in the ADT plus D arm. Limitations included the retrospective analysis of metastatic extent and the lack of statistical power to detect a significant difference in subgroups.
The post hoc analyses of the GETUG-AFU15 study demonstrated a nonsignificant 20% reduction in the risk of death in the HVD subgroup. Patients with LVD had no survival improvement with early D.
In this study, docetaxel added to castration did not improve survival in patients with metastatic hormone-sensitive prostate cancer, partly due to methodological issues. However, early chemotherapy should be discussed with all patients, given the data of three randomized trials including GETUG-AFU15.
European urology. 2015 Nov 20 [Epub ahead of print]
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, Michel Soulié, Laurence Albiges, Franck Priou, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Frédéric Rolland, Christine Théodore, Gael Deplanque, Jean-Marc Ferrero, Stéphane Culine, Loïc Mourey, Philippe Beuzeboc, Muriel Habibian, Stéphane Oudard, Karim Fizazi, GETUG
Medical Oncology, Institut Paoli-Calmettes, Marseille, France. Biostatistics, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille Université, UMR_S 912 (SESSTIM), IRD, Marseille, France; INSERM, UMR_S 912 (SESSTIM), Marseille, France. , Medical Oncology, Centre François Baclesse - CHU Côte de Nacre, Caen, France. , Urology Department, Centre Hospitalier Universitaire Rangueil, Toulouse, France. , Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. , Medical Oncology, Centre Hospitalier Les Oudairies, La Roche-sur-Yon, France. , Radiotherapy Department, Clinique Pasteur, Toulouse, France. , Department of Medical Oncology, Centre Paul Papin, Angers, France. , Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France. , Medical Oncology, Centre Eugène Marquis, Rennes, France. , Medical Oncology, Centre René Gauducheau, Saint-Herblain, France. , Medical Oncology, Hôpital Foch, Suresnes, France. , Medical Oncology, Groupe Hospitalier Saint Joseph, Paris, France. , Medical Oncology, Centre Antoine Lacassagne, Nice, France. , Medical Oncology, Hôpital Saint-Louis, Paris, France. , Institut Claudius Régaud, Toulouse, France. , Medical Oncology, Institut Curie, Paris, France. , UNICANCER, Paris, France. , Medical Oncology Department, Georges Pompidou Hospital and René Descartes University, Paris, France. , Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.